Clinical trials: Covid19 Vaccine
Covid19
Immunogenicity and Safety Study of SK SARS-CoV-2 Recombinant Nanoparticle Vaccine (GBP510) Adjuvanted With AS03 (COVID-19)
This is a 2-Stage, Phase III, randomized, active-controlled, observer-blind, parallel-group, multi-center study to compare the immunogenicity and safety of SK SARS-CoV-2 recombinant nanoparticle vaccine adjuvanted with AS03…
- Trial name
- NCT05007951
- Testing
- GBP510 adjuvanted with AS03 (Receptor-Binding Domain(RBD) 25ug/dose), ChAdOx1-S not less than 2.5 × 10^8 infectious units
- Where
- 38 sites in New Zealand, Philippines and 4 more
- Volunteers
- 4,036 people, healthy volunteers welcome
- Sponsor
- SK Bioscience Co., Ltd.
Misinformation, Vaccine Hesitancy
Brief Digital Intervention to Increase COVID-19 Vaccination Among Individuals With Anxiety or Depression
The COVID-19 pandemic has led to a mis/disinformation ecosystem that promotes divergent views of vaccine efficacy, as well as the legitimacy of science and medicine.
- Conditions
- Misinformation, Vaccine Hesitancy, Anxiety, Depression
- Trial name
- NCT06119854
- Testing
- Attitudinal inoculation, Cognitive-behavioral therapy-informed intervention, Conventional public health messaging
- Where
- United States
- Volunteers
- 1,419 people
- Sponsor
- City University of New York, School of Public Health
Alopecia Areata, Alopecia Totalis
The Epidemiology, Management and Comorbidities in Alopecia Areata in Czech Republic
The study series consists of three studies with the aim to assess the incidence, prevalence, risk factors, comorbidities and management of patients with alopecia areata in Czech Republic based on the patients and registry of a…
- Conditions
- Alopecia Areata, Alopecia Totalis, Alopecia Universalis, Alopecia Areata (& Ophiasis)
- Trial name
- NCT05098600
- Testing
- Exposure of interest
- Where
- Czechia
- Volunteers
- 123 people
- Sponsor
- Faculty Hospital Kralovske Vinohrady
COVID-19
Safety and Immunogenicity Study of AdCLD-CoV19: A COVID-19 Preventive Vaccine in Healthy Volunteers
This is a Phase 1/2a clinical trial to assess the safety and immunogenicity of AdCLD-CoV19 in healthy adults.
- Trial name
- NCT04666012
- Testing
- AdCLD-CoV19
- Where
- 5 sites in South Korea
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Cellid Co., Ltd.
COVID-19 Vaccine, Older Adults
Safety and Immunogenicity of COVID-19 Vaccine Administered in Older Adults
The COVID-19 pandemic is causing unprecedented morbidity and mortality.The safe and effective Novel coronavirus vaccine is an effective means to block the transmission of the virus by building up the immune barrier of the…
- Trial name
- NCT05012800
- Testing
- COVID-19 Vaccine
- Where
- China
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Beijing 302 Hospital
COVID-19 Pandemic
Fourth COVID-19 Vaccine Dose- mRNA1273
The Omicron variant of concern (VOC) is currently rapidly spreading worldwide, with extremely high transmission rates, with an estimated R of >3.
- Trial name
- NCT05230953
- Testing
- mRNA1273 vaccine
- Where
- Israel
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Sheba Medical Center
Participants With or Without Stable Co-morbidities Associated With Progression to Severe COVID-19 at Different Stages of the Protocol
A Study of Ad26.COV2.S for the Prevention of SARS-CoV-2-Mediated COVID-19 in Adult Participants
The study will evaluate the efficacy of Ad26.COV2.S in the prevention of molecularly confirmed moderate to severe/critical COVID-19, as compared to placebo, in adult participants.
- Trial name
- ENSEMBLE (NCT04505722)
- Testing
- Ad26.COV2.S
- Where
- 225 sites in United States, Argentina and 6 more
- Volunteers
- 44,325 people, healthy volunteers welcome
- Sponsor
- Janssen Vaccines & Prevention B.V.
COVID-19, Coronavirus Infections
Safety, Tolerability, and Immunogenicity of Trivalent Coronavirus Vaccine Candidate VBI-2901a
VBI-2901a is an investigational vaccine candidate that uses enveloped virus-like particles (eVLPs) to express the spike proteins of three coronaviruses: SARS-CoV-2 (the virus that causes COVID-19 disease), SARS-CoV-1 and…
- Trial name
- NCT05548439
- Testing
- VBI-2901a
- Where
- 7 sites in Canada
- Volunteers
- 103 people, healthy volunteers welcome
- Sponsor
- VBI Vaccines Inc.
COVID-19 Vaccine
ARVAC-A New Recombinant Coronavirus Disease 2019 (COVID-19) Vaccine
The goals of this clinical trial are: 1. Phase 2: to test a gamma adapted recombinant vaccine against SARS-CoV-2 in healthy adult volunteers, previously vaccinated against the SARS-CoV-2 virus. 2.
- Trial name
- ARVAC-F2/3 (NCT05752201)
- Testing
- Gamma Variant RBD-based ARVAC-CG vaccine, Omicron Variant RBD-based ARVAC-CG vaccine, Bivalent RBD-based ARVAC-CG vaccine
- Where
- 11 sites in Argentina
- Volunteers
- 2,014 people, healthy volunteers welcome
- Sponsor
- Centro de Educación Medica e Investigaciones Clínicas Norberto Quirno
COVID-19
A Study to Evaluate The Efficacy, Safety and Immunogenicity of Inactivated SARS-CoV-2 Vaccines (Vero Cell) in Healthy Population Aged 18 Years Old and Above
This is a multicenter, randomized, double blind, parallel placebo controlled, phase 3 clinical trial to evaluate the protective efficacy, safety and immunogenicity of inactivated SARS-CoV-2 vaccines in healthy population 18 years…
- Trial name
- COVID-19 (NCT04510207)
- Testing
- Inactivated SARS-CoV-2 Vaccine (Vero cell)
- Where
- 6 sites in Bahrain, Egypt and 2 more
- Volunteers
- 44,101 people, healthy volunteers welcome
- Sponsor
- China National Biotec Group Company Limited
Covid19 Vaccine
A Study to Evaluate Immunogenicity and Safety of MVC-COV1901 Compared With AZD1222 Against COVID-19 in Adults
The purpose of this study is to assess the immunogenicity and safety of MVC-COV1901 vaccine compared to AZD1222 in heathy adults.
- Trial name
- NCT05011526
- Testing
- MVC-COV1901, AZD1222
- Where
- 2 sites in Paraguay
- Volunteers
- 1,030 people, healthy volunteers welcome
- Sponsor
- Medigen Vaccine Biologics Corp.
COVID-19, SARS-CoV-2 Acute Respiratory Disease
Safety and Immunogenicity of Recombinant Protein RBD Fusion Dimer Vaccine Against the Virus That Cause COVID-19, Known as Severe Acute Respiratoy Syndrome Coronavirus 2 (SARS-CoV-2)
This is a Phase IIb, randomized, controlled, observer-blinded, clinical trial to evaluate safety and immunogenicity of COVID-19 Vaccine HIPRA in adult healthy volunteers in Vietnam
- Trial name
- NCT05142514
- Testing
- COVID-19 Vaccine HIPRA, Cominarty (Pfizer-BioNtech)
- Where
- Vietnam
- Volunteers
- 629 people, healthy volunteers welcome
- Sponsor
- Hipra Scientific, S.L.U
COVID-19
Safety and Serum Virus Neutralizing Antibody Responses of VYD2311, a COVID-19 Vaccine, and Coadministered VYD2311 With a COVID-19 Vaccine
The main purposes of this research study are to measure the safety (whether it causes any side effects), tolerability (if it does cause any side effects, how well your body is able to handle them), and reactions, both local at…
- Trial name
- LIBERTY (NCT07655180)
- Testing
- COVID-19 mRNA vaccine, VYD2311
- Where
- United States
- Volunteers
- 210 people, healthy volunteers welcome
- Sponsor
- Invivyd, Inc.
Covid19, Corona Virus Infection
Covid-19 Vaccine Effectiveness in Healthcare Personnel in Clalit Health Services in Israel (CoVEHPI)
Although clinical trials for approved COVID-19 vaccines demonstrated efficacy of the vaccine in preventing symptomatic infection, many questions about vaccine effectiveness, such as the effectiveness of COVID-19 vaccine in…
- Conditions
- Covid19, Corona Virus Infection, Vaccine Effectiveness
- Trial name
- CoVEHPI (NCT04709003)
- Testing
- Serologic test, Respiratory swabs
- Where
- 6 sites in Israel
- Volunteers
- 1,567 people, healthy volunteers welcome
- Sponsor
- Clalit Health Services
SARS CoV 2 Infection
Study to Evaluate the Safety & Immunogenicity of IMNN-101 Administered in Healthy Adults Previously Vaccinated Against SARS-CoV-2
This is an open-label phase 1/2, dose-escalation study. Participants will receive a single intramuscular (IM) dose of IMNN-101 on Day 0 in the deltoid muscle and will be followed through 12 months post-vaccination (through Study…
- Trial name
- NCT06283459
- Testing
- IMNN-101
- Where
- 2 sites in United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Imunon
Covid19
Clinical Trial of Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) Against COVID-19
This study is a phase III clinical trial to evaluate efficacy, reactogenicity and safety of the vaccine Ad5-nCoV compared with placebo in volunteers at the age from 18 to 85 years，with the randomized, double-blind design
- Trial name
- NCT04540419
- Testing
- Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector)
- Where
- 7 sites in Russia
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- NPO Petrovax
Vaccine Hesitancy
Investigation on the Hesitancy of COVID-19 Vaccination Among Liver Transplant Recipients in China
On WeChat platform, through a point-to-point connection, and carry on the questionnaire survey to collect information of liver transplant recipients followed-up by the department of Liver Surgery, Renji Hospital Shanghai Jiao…
- Trial name
- NCT05532592
- Testing
- Perceptions and attitudes towards COVID-19 and COVID-19 vaccine
- Where
- China
- Volunteers
- 449 people
- Sponsor
- RenJi Hospital
Lung Cancer, Covid19
Anti-SARS-COV2 Vaccination Study in Lung Cancer Patients
Observational and multicenter retrospective study of data collection in hospital centers throughout the Spanish geography. This study aims to be nationwide in order to study general common variables of the patients, as well as…
- Trial name
- VAC-CaP (NCT05009030)
- Testing
- COVID-19 vaccine
- Where
- 51 sites in Spain
- Volunteers
- 794 people
- Sponsor
- Fundación GECP
SARS-CoV2 Infection, Coronavirus Infection
Fourth Dose of mRNA COVID-19 Vaccine in Residents of LTCFs
This study is a multi-centre, blinded, randomized controlled trial. LTCF residents ≥ 65 years who have received three doses of mRNA vaccine will be randomized to vaccination with a fourth dose of Pfizer-BioNtech mRNA- COVID-19…
- Trial name
- NCT04978038
- Testing
- mRNA- COVID-19, Prevnar13
- Where
- Canada
- Volunteers
- 414 people, healthy volunteers welcome
- Sponsor
- Mark Loeb
Hematologic Disorders and Bone Marrow Failure, Hematopoietic Stem Cell Transplantation (HSCT) or Cellular Therapy (CART)
Response to SARS-CoV-2 Vaccine in Stem Cell Transplant and Cellular Therapy Patients
For many patients with hematologic disorders and bone marrow failure, hematopoietic stem cell transplantation (HSCT) or cellular therapy (CART) offers a curative treatment option.
- Trial name
- NCT04723706
- Testing
- COVID-19 serology IgG
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- Henry Ford Health System
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.